Lorrain Daniel S. 4

What Happened

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), exercised stock options and immediately sold the resulting shares. On Feb 24, 2026 he exercised 4,300 options at $1.01/share (cost $4,343) and sold those 4,300 shares for a weighted average $16.03/share (proceeds $68,936). On Feb 25, 2026 he exercised 3,824 options at $1.01/share (cost $3,862) and sold those 3,824 shares for a weighted average $16.01/share (proceeds $61,228). Total proceeds from the sales were $130,164; total exercise cost was $8,205, for net proceeds of about $121,959. The filing also reports the related derivative instruments were disposed at $0.00 (i.e., the options were converted/exercised).

Key Details

• Transaction dates: Feb 24–25, 2026; Form 4 filed Feb 26, 2026 (timely filing).
• Exercise price: $1.01 per share for both exercises; options are fully vested (F4).
• Sales: 4,300 shares sold at a weighted avg $16.03 (range $16.00–$16.15 per F2) and 3,824 shares sold at a weighted avg $16.01 (range $16.00–$16.05 per F3).
• Total shares involved: 8,124 shares sold; total gross proceeds ≈ $130,164; net after exercise ≈ $121,959.
• Plan/condition: Transactions were executed under a 10b5-1 trading plan adopted Sept 23, 2025 (F1).
• Shares owned after transaction: Not disclosed in the supplied Form 4 details.

Context

• This was an option exercise followed by same-day sales (a cashless-style transaction): M = option exercise/conversion, S = open-market sale. The reported $0.00 disposals reflect removal of the derivative (the options) upon exercise.
• Sales executed under a 10b5-1 plan are typically pre-arranged and routine; the filing is factual and does not indicate insider motivation.